Omada Health's (OMDA) Sell (D) Rating Reiterated at Weiss Ratings

Key Points

• Omada Health's stock has a "sell (d)" rating reiterated by Weiss Ratings, indicating ongoing concerns among analysts regarding the company's performance.
• Despite the sell rating from Weiss, other analysts have varying perspectives, with seven showing a Buy rating and an average price target of $25.50.
• In its latest earnings report, Omada Health reported a loss of ($0.22) EPS, missing estimates, but achieved revenue of $61.37 million, surpassing expectations.

Omada Health (NASDAQ:OMDA - Get Free Report)'s stock had its "sell (d)" rating restated by equities researchers at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

OMDA has been the topic of several other reports. Canaccord Genuity Group increased their price target on shares of Omada Health from $27.00 to $28.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Morgan Stanley initiated coverage on shares of Omada Health in a research report on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 price target on the stock. Robert W. Baird started coverage on shares of Omada Health in a research report on Friday, September 5th. They issued a "neutral" rating and a $24.00 price target on the stock. JPMorgan Chase & Co. started coverage on shares of Omada Health in a research report on Tuesday, July 1st. They set an "overweight" rating and a $19.00 target price on the stock. Finally, Evercore ISI set a $27.00 target price on shares of Omada Health in a research report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Omada Health has an average rating of "Moderate Buy" and an average target price of $25.50.

Omada Health Trading Up 0.7%

OMDA stock opened at $25.87 on Friday. The firm has a 50 day simple moving average of $23.21. Omada Health has a 12 month low of $14.14 and a 12 month high of $28.40.

Omada Health (NASDAQ:OMDA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.07). The firm had revenue of $61.37 million for the quarter, compared to analyst estimates of $55.17 million. Omada Health has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Omada Health

Large investors have recently bought and sold shares of the stock. Sanofi purchased a new position in Omada Health during the second quarter worth approximately $9,606,000. Fortress Investment Group LLC purchased a new position in Omada Health during the second quarter worth approximately $2,878,000. Federated Hermes Inc. purchased a new position in Omada Health during the second quarter worth approximately $9,150,000. Norges Bank purchased a new position in Omada Health during the second quarter worth approximately $5,490,000. Finally, XTX Topco Ltd purchased a new position in Omada Health during the second quarter worth approximately $414,000.

About Omada Health

Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.